Room 201 (Washington DC Convention Center)
Bridging the Gap Between Preclinical Pain Models and Clinical Efficacy in Pain
Several recent high profile pain programs that looked promising in the preclinical phase of development ultimately failed as analgesics in pivotal phase III clinical trials. Conversely, a number of clinically useful analgesics have been “discovered” only after they had been approved for other indications. It is also likely that some development programs were halted prematurely due to lack of efficacy in available preclinical models, discarding potentially useful analgesics in the process. This symposium focuses on how preclinical analgesic drug development can be improved to reduce the number of false positive and false negatives. Dr. Bilsky will moderate and provide background information on the topic. Dr. Vanderah will describe recent advances in rodent models of nociception (e.g., cancer pain, arthritis and neuropathic models). Dr. Negus will discuss alternatives to relying exclusively on pain-evoked behaviors (e.g., incorporating measures of pain suppressed behaviors and effects of putative analgesics). Dr. Sandra Comer will provide a clinical perspective of assessing pain and analgesic effects in humans. The panel will conclude with recommendations on how preclinical drug assessment can be best implemented to make the drug discovery process more efficient and accurate.
Moderator:Edward J. Bilsky, PhD
Presenters:S. Stevens Negus, PhD
Sandra Comer, PhD
Todd Vanderah, PhD
 Bridging the Gap Between Preclinical Pain Models and Clinical Efficacy in Pain
Edward J. Bilsky, PhD
 Novel Approaches to Preclinical Assessment of Pain and Analgesia: Focus on Behavioral Measures

S. Steven Negus, PhD
 Assessments of pain and analgesic response in human research volunteers

Sandra Comer, PhD
 Bridging the Gap Between Preclinical Pain Models and Clinical Efficacy in Pain-3
Todd Vanderah, PhD

Return to the Schedule of Events

See more of Symposia